U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...

for the use of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma (HCC). According to ...

According to Zhen, the trial comparing nivolumab (Opdivo) plus chemotherapy vs chemotherapy alone led to an overall survival (OS) benefit in patients with a PD-L1 combined positive score (CPS) of 5 or ...

Different parts of Medicare can provide coverage for cancer treatments, including Opdivo. The coverage will depend on various factors, such as the phase of treatment and where a person receives ...

Renewable energy is energy that comes from sources that are readily replenishable on short-timescales. Examples of these are solar radiation, wind, and biomass. The performance of kesterite solar ...

There’s little research on CBD for energy and focus. However, if you’re interested in giving it a try, here are some products our testers suggest. Share on Pinterest Research on cannabidiol ...

The prognostic value of HER2 gene dosage and heterogeneity at a single-cell resolution in gastroesophageal adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

The review also highlights a growing trend in combining MC with immunotherapy and targeted treatments like nivolumab and pazopanib to enhance its therapeutic effects. However, despite these ...

The International Day of Clean Energy on 26 January was declared by the General Assembly (resolution A/77/327) as a call to raise awareness and mobilize action for a just and inclusive transition to ...

President Trump has declared an energy emergency, which his team has said would unlock additional powers to jump-start production. Speaking about the declaration from behind the desk of the Oval O ...

The BLA submission is based on the primary analysis data of the IGNYTE trial, which evaluated RP1 in combination with nivolumab in patients with advanced melanoma who had not responded to anti-PD-1 ...

Industrials shares surged by 1.8% on Tuesday. In trading on Tuesday, energy shares fell by 0.6%. Charles Schwab Corporation SCHW reported better-than-expected fourth-quarter financial results.